Telmisartan is indicated for the treatment of hypertension, and the approval has been received for 20mg, 40mg and 80mg tablets.
Telmisartan is Glenmark's generic version of Boehringer Ingelheim's Micardis.
Glenmark will commence distribution of the product immediately according to the company's statement. For the 12 month period ending March 2014, Telmisartan garnered annual sales of $250 Million according to IMS Health.
Glenmark's current portfolio consists of 92 products authorized for distribution in the US marketplace, and 73 ANDA's pending approval with the USFDA.